Zoetis Welcomes Officials to Open New State-of-the-Art Facility in Lincoln
August 09 2023 - 6:33PM
Business Wire
Zoetis:
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20230809927875/en/
Zoetis CEO Kristin Peck (center), cuts
the ribbon, marking the official opening of the company's new
monoclonal antibodies (mAbs) expansion. Ms. Peck is pictured with
Zoetis leadership and local officials. Source: Zoetis
NEWS FACTS
- Today, Zoetis, the world leader in Animal Health, marked the
official opening of its new monoclonal antibodies (mAbs) expansion
with a ribbon cutting ceremony at its site in Lincoln, Neb.
- The ceremony was attended by local officials, including U.S.
Senator Pete Ricketts, Lincoln Mayor Gaylor Baird and key company
leaders including Zoetis CEO Kristin Peck, and President of Global
Manufacturing and Supply, Nick Ashton.
- This new facility will enable the Lincoln manufacturing site to
increase production of products that control osteoarthritis pain in
dogs and cats – the company’s largest growing area of need for pet
care customers.
- The new facility will also be a home for future innovation and
serve as a Veterinary Medicine R&D registration facility for
the company as it looks to expand its portfolio with future
innovations.
ZOETIS IN LINCOLN
- Zoetis’ Lincoln site in Neb. is a crucial manufacturing plant
within the Zoetis supply network. It plays a vital role in
producing biologics, biopharmaceuticals and pharmaceutical products
for animals.
- With a workforce of nearly 950 colleagues operating 24/7,
year-round, the site manufactures an impressive 1,239 finished
goods, or stock keeping units (SKUs), for distribution to more than
100 countries worldwide.
- Located on 145 acres in the west side of Lincoln, Neb., the
campus spans 1.4 million square feet, housing manufacturing,
testing, and facility support buildings.
- Zoetis produces some of its flagship vaccines and
pharmaceutical products in Lincoln, including:
- Cytopoint® - a monoclonal antibody that provides effective
treatment for dogs against allergic or atopic dermatitis,
- Vanguard® - a line of vaccines to keep dogs and cats protected
from common diseases,
- BoviShield® - a line of vaccines shown to be efficacious
against respiratory diseases, and reproductive diseases for the
specific BoviShield FP line, in cattle,
- Simparica® (sarolaner) - a parasiticide that protects dogs from
ticks and fleas. Simparica® belongs to the Isoxazoline drug class
and has been associated with neurologic adverse reactions including
seizures. Use with caution in dogs with a history of these
conditions. The most common side effects are vomiting and
diarrhea.
- Rimadyl® (carprofen) - a pharmaceutical product for relief of
pain associated with osteoarthritis in dogs. Rimadyl® belongs to
the NSAIDS drug class and has been associated with
gastrointestinal, kidney and liver side effects; contact your dog’s
veterinarian if side effects occur. Evaluation for pre-existing
conditions and regular monitoring are recommended for pets on
Rimadyl®. Use with other NSAIDS or corticosteroids should be
avoided.
- Zoetis and its predecessors have long maintained a presence in
the Lincoln area. In the early 20th century, pharmaceutical firms
and distributors such as Norden Laboratories established facilities
in Nebraska that evolved over time. More recent incarnations of
these animal health companies, including Zoetis, have continued to
play an important economic role in the Lincoln community.
QUOTES
“We are excited to celebrate the opening of our new facility
right here in Nebraska! This community is important to us as we
have been welcomed to do business here for over a decade as Zoetis,
delivering high quality, reliable supply of our animal health
products for customers around the world,” said Chris Rasmussen,
Zoetis Site Leader, Lincoln. “For the last 10 years, we have been
able to grow our business, expand our site and bring more than 900
jobs to the site in Lincoln based on the world’s fundamental need
for ways to keep animals healthy.”
“Our Zoetis Lincoln team has always demonstrated a commitment to
the world’s veterinary community and livestock producers by
delivering purpose-driven innovation that transforms the lives of
animals from cats to cattle -- and it’s why we continue to invest
in the operations and colleagues here,” said Kristin Peck, CEO
Zoetis. “This new monoclonal antibody (mAbs) expansion will enable
us to continue meeting the needs of our customers in one of the
fastest growing areas of animal health, and our team in Lincoln
will be critical to that future.”
ABOUT ZOETIS
As the world’s leading animal health company, Zoetis is driven
by a singular purpose: to nurture our world and humankind by
advancing care for animals. After innovating ways to predict,
prevent, detect, and treat animal illness for more than 70 years,
Zoetis continues to stand by those raising and caring for animals
worldwide -- from veterinarians and pet owners to livestock farmers
and ranchers. The company’s leading portfolio and pipeline of
medicines, vaccines, diagnostics and technologies make a difference
in over 100 countries. A Fortune 500 company, Zoetis generated
revenue of $8.1 billion in 2022 with approximately 13,800
employees. For more information, visit www.zoetis.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230809927875/en/
Media:
Bill Price Mobile: 908-251-1972 william.price@zoetis.com
Robyn Velardo Mobile: 973-936-0481 Robyn.velardo@zoetis.com
Zoetis (NYSE:ZTS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Zoetis (NYSE:ZTS)
Historical Stock Chart
From Jul 2023 to Jul 2024